Crossmark

Effectiveness and safety of biosimilars in pediatric inflammatory bowel diseases: an observational longitudinal study on the French National Health Data System

Crossref DOI link: https://doi.org/10.1007/s12519-024-00873-4

Published Online: 2025-01-23

Published Print: 2025-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Jourdain, Hugo https://orcid.org/0000-0001-8035-7517
Hoisnard, Léa

Sbidian, Emilie

Zureik, Mahmoud
License Information

Text and Data Mining valid from 2025-01-01

Version of Record valid from 2025-01-01
More Information

Article History

Received: 4 September 2024

Accepted: 11 December 2024

First Online: 23 January 2025

Change Date: 5 March 2025

Change Type: Update

Change Details: Supplementary file was missing from this article and has now been uploaded.

Declarations

:

: The authors are employees of the French National Health Insurance (CNAM), the French National Agency for Medicines and Health Products Safety (ANSM) and the Assistance Publique – Hôpitaux de Paris (AP-HP). No financial or non-financial benefits have been received or will be received from any party related directly or indirectly to the subject of this article.

: Given that data are anonymous, no informed consent to participate or publish was required.

: EPI-PHARE has permanent regulatory access to the data via its constitutive bodies ANSM and CNAM, thus this present work did not require the approval from the French Data Protection Authority (CNIL). The study was registered on the study register of EPI-PHARE under the number T-2023–05-455.

Document is current

Any future updates will be listed below